OKYO Pharma Announces Purchase of Shares by Director

Rhea-AI Summary

OKYO Pharma (Nasdaq: OKYO) reported that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on Nasdaq at $1.48 per share, increasing his total holding to 35,201 shares. The company is a clinical-stage biopharmaceutical developer of investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares listed on the Nasdaq Capital Market.

According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients to assess a single-dose regimen.

News Market Reaction – OKYO

-2.63%

2 alerts

-2.63% Session close to close

+6.9% Peak Tracked

$79.77M Market Cap

1.2x Rel. Volume

In the Jul 23 session, OKYO declined 2.63%, reflecting a moderate negative market reaction. Argus tracked a peak move of +6.9% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

News ID 1085287 recorded a 5.56% 24-hour reaction after a prior director purchase. The effective F-3...

Analysis

News ID 1085287 recorded a 5.56% 24-hour reaction after a prior director purchase. The effective F-3 shelf and stated $200,000,000 capacity remain financing context; future filings provide the relevant watchpoint.

Key Figures

Shares purchased: 5,000 shares Purchase price: $1.48 per share Total holding: 35,201 shares +2 more

5 metrics

Shares purchased 5,000 shares Director purchase on NASDAQ

Purchase price $1.48 per share Director purchase

Total holding 35,201 shares Director's holding after purchase

Trial phase Phase 3 Global pivotal clinical trial planned for NCP

Planned enrollment Approximately 111 patients Planned Phase 3 trial for NCP

Historical Context

5 past events · Latest: Jul 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 22	Director share purchase	Positive	+5.6%	Director purchased 3,500 shares; the stock recorded a positive 24-hour reaction.
Jul 22	Officer share purchase	Positive	+5.6%	Chief medical officer purchased 20,000 shares; the stock recorded a positive 24-hour reaction.
Jul 21	Conference presentation	Neutral	+5.1%	Company presentation announcement preceded a positive 24-hour reaction in the following session.
Jul 21	Chairman share purchase	Positive	+5.1%	Chairman purchased 25,000 shares; the stock recorded a positive 24-hour reaction.
Jul 20	Annual report	Positive	-4.2%	Annual report cited funding and Phase 3 plans; shares recorded a negative reaction.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history showed positive reactions to insider-purchase notices, while the annual-report and clinical update was followed by a negative reaction.

Key Terms

neuropathic corneal pain, phase 3 pivotal clinical trial, single-dose regimen

3 terms

neuropathic corneal pain medical

"therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

phase 3 pivotal clinical trial medical

"initiate a global Phase 3 pivotal clinical trial"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"evaluate a single-dose regimen of urcosimod"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

FAQ

What insider share purchase did OKYO Pharma (NASDAQ: OKYO) announce on July 23, 2026?

OKYO Pharma announced that director John Brancaccio bought 5,000 ordinary shares at $1.48 per share. According to OKYO Pharma, this transaction increased his total holding to 35,201 shares, reflecting his individual investment position in the company’s Nasdaq-listed equity.

How many OKYO Pharma (OKYO) shares does director John Brancaccio now hold?

Following his latest purchase, John Brancaccio now holds 35,201 OKYO Pharma ordinary shares. According to OKYO Pharma, this reflects the addition of 5,000 shares acquired on Nasdaq at a price of $1.48 per share in the disclosed transaction.

What Phase 3 clinical trial is OKYO Pharma planning for urcosimod in neuropathic corneal pain?

OKYO Pharma plans a global Phase 3 pivotal trial of urcosimod for neuropathic corneal pain. According to OKYO Pharma, the study is expected in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen in this indication.

When will OKYO Pharma’s planned Phase 3 trial for NCP with urcosimod begin and how many patients are expected?

OKYO Pharma plans to initiate the Phase 3 NCP trial in the second half of this year. According to OKYO Pharma, the global pivotal study is expected to enroll approximately 111 patients to assess a single-dose urcosimod regimen.

On which exchange are OKYO Pharma ordinary shares traded and under what ticker symbol?

OKYO Pharma ordinary shares trade on the Nasdaq Capital Market under the ticker symbol OKYO. According to OKYO Pharma, the company is a clinical-stage biopharmaceutical developer focused on therapies for neuropathic corneal pain and anterior segment eye diseases.